Payment overview · 2025
General Payments
$1,702.04
94 reported records · 16 companies
Healthcare provider profile · identity verified
D. Bryan Dye, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PURCELL, OK · NPI 1437192903
Verified facts
What the public records show
CMS Open Payments records show D. Bryan Dye, M.D. received $1,702.04 in general payments during 2025 across 94 reported records.
Novo Nordisk Inc accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 451 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $381.24 | 22.4% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $306.43 | 18.0% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $219.59 | 12.9% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $169.49 | 10.0% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.74 | 5.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $88.99 | 5.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $80.26 | 4.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $77.05 | 4.5% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $72.32 | 4.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.65 | 3.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.08 | 2.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.43 | 2.7% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.23 | 1.1% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.31 | 0.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.18 | 0.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.05 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,702.04 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $289.91 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $267.32 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $242.29 | 18 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $151.36 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $122.41 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $105.51 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $105.51 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $96.52 | 4 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $91.33 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $91.33 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $90.93 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $88.99 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $88.85 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $77.05 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $72.32 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $64.14 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $64.14 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $64.14 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.18 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.18 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.65 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.08 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 451 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 295 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
295 | 57 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
295 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
108 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
451 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 961 | 243 |
| Atorvastatin Calcium | Atorvastatin Calcium | 846 | 239 |
| Amlodipine Besylate | Amlodipine Besylate | 563 | 167 |
| Potassium Chloride | Potassium Chloride | 458 | 114 |
| Gabapentin | Gabapentin | 454 | 114 |
| Eliquis | Apixaban | 451 | 67 |
| Lisinopril | Lisinopril | 422 | 118 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 383 | 65 |
| Furosemide | Furosemide | 381 | 102 |
| Losartan Potassium | Losartan Potassium | 380 | 100 |
| Omeprazole | Omeprazole | 351 | 96 |
| Sertraline Hcl | Sertraline Hcl | 309 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 84 |
| Jardiance | Empagliflozin | 295 | 57 |
| Metformin Hcl | Metformin Hcl | 281 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 260 | 108 |
| Meloxicam | Meloxicam | 249 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 79 |
| Duloxetine Hcl | Duloxetine Hcl | 234 | 55 |
| Tramadol Hcl | Tramadol Hcl | 233 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 59 |
| Alprazolam | Alprazolam | 209 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 206 | 55 |
| Pregabalin | Pregabalin | 202 | 42 |
| Trazodone Hcl | Trazodone Hcl | 200 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 60 |
| Famotidine | Famotidine | 188 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 184 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 160 | 38 |
| Ozempic | Semaglutide | 158 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 64 |
| Prednisone | Prednisone | 151 | 104 |
| Mirtazapine | Mirtazapine | 141 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 139 | 22 |
| Donepezil Hcl | Donepezil Hcl | 138 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 39 |
| Memantine Hcl | Memantine Hcl | 134 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 46 |
| Carvedilol | Carvedilol | 129 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 35 |
| Montelukast Sodium | Montelukast Sodium | 126 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 21 |
| Sucralfate | Sucralfate | 120 | 31 |
| Levetiracetam | Levetiracetam | 118 | 16 |
| Metformin Hcl Er | Metformin Hcl | 116 | 30 |
| Simvastatin | Simvastatin | 113 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 31 |
| Trulicity | Dulaglutide | 108 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 33 |
| Alendronate Sodium | Alendronate Sodium | 99 | 32 |
| Allopurinol | Allopurinol | 91 | 28 |
| Buspirone Hcl | Buspirone Hcl | 89 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 88 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 31 |
| Ibuprofen | Ibuprofen | 86 | 37 |
| Amiodarone Hcl | Amiodarone Hcl | 83 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 15 |
| Myrbetriq | Mirabegron | 79 | 22 |
| Ezetimibe | Ezetimibe | 74 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 21 |
| Ondansetron Odt | Ondansetron | 72 | 29 |
| Divalproex Sodium | Divalproex Sodium | 71 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 28 |
| Temazepam | Temazepam | 71 | 18 |
| Estradiol | Estradiol | 70 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 69 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 52 |
| Atenolol | Atenolol | 65 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 39 |
| Finasteride | Finasteride | 63 | 23 |
| Baclofen | Baclofen | 62 | 11 |
| Lorazepam | Lorazepam | 62 | 13 |
| Aripiprazole | Aripiprazole | 61 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 15 |
| Cephalexin | Cephalexin | 60 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 43 |
| Nystop | Nystatin | 59 | 14 |
| Spironolactone | Spironolactone | 59 | 21 |
| Bupropion Xl | Bupropion Hcl | 57 | 15 |
| Synthroid | Levothyroxine Sodium | 57 | 15 |
| Chlorthalidone | Chlorthalidone | 56 | 23 |
| Clonidine Hcl | Clonidine Hcl | 53 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 20 |
| Mounjaro | Tirzepatide | 51 | 20 |
| Primidone | Primidone | 51 | suppressed |
| Diazepam | Diazepam | 50 | 17 |
| Fluconazole | Fluconazole | 50 | 26 |
| Methocarbamol | Methocarbamol | 50 | 16 |
| Naproxen | Naproxen | 50 | 17 |
| Olanzapine | Olanzapine | 50 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | suppressed |
| Topiramate | Topiramate | 49 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 48 | 16 |
| Azithromycin | Azithromycin | 48 | 44 |
| Celecoxib | Celecoxib | 48 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Clonazepam | Clonazepam | 45 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 41 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 40 | 16 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | 12 |
| Xarelto | Rivaroxaban | 36 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Nystatin | Nystatin | 33 | 23 |
| Risperidone | Risperidone | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 20 |
| Modafinil | Modafinil | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 30 | 15 |
| Digoxin | Digoxin | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Movantik | Naloxegol Oxalate | 28 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 15 |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Valacyclovir | Valacyclovir Hcl | 23 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | 11 |
| Wegovy | Semaglutide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Klayesta | Nystatin | 17 | 11 |
| Zaleplon | Zaleplon | 17 | suppressed |
| Acetic Acid | Acetic Acid | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Riluzole | Riluzole | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,702.04 · 94 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GEMTESA, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, Rybelsus, SHINGRIX, SKYCLARYS, Saxenda, TRINTELLIX, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error